文献速递脑血管病外科神经重症

动脉瘤性蛛网膜下腔出血后神经重症监护患者的挥发性麻醉药镇静:对迟发性脑缺血、脑血管痉挛及功能预后的影响

Volatile Sedation in Neurointensive Care Patients After Aneurysmal Subarachnoid Hemorrhage: Effects on Delayed Cerebral Ischemia, Cerebral Vasospasm, and Functional Outcome.
PubMed 文献 · World Neurosurg · 2024-08-23

该回顾性研究纳入2016至2022年间接受至少180小时镇静的99例动脉瘤性蛛网膜下腔出血机械通气患者,比较静脉镇静与挥发性麻醉药(异氟烷或七氟烷)镇静对迟发性脑缺血、脑血管痉挛、迟发性脑缺血相关梗死及功能预后的影响。结果显示两组在上述结局上均无显著差异,多因素回归中挥发性麻醉药使用对迟发性脑缺血相关梗死和功能预后无影响。

要点

  • 挥发性麻醉药镇静与静脉镇静相比,迟发性脑缺血、脑血管痉挛、迟发性脑缺血相关梗死及功能预后均无显著差异。
  • 多因素回归显示挥发性麻醉药使用对迟发性脑缺血相关梗死和功能预后无影响。
  • 尽管未能证实神经保护效应,结果提示动脉瘤性蛛网膜下腔出血后挥发性镇静对患者结局无负面影响。

核心结论

  • 动脉瘤性蛛网膜下腔出血患者的挥发性镇静与迟发性脑缺血、脑血管痉挛、迟发性脑缺血相关梗死或功能预后的发生率无关。
  • 尽管未能证实挥发性麻醉药的神经保护效应,结果提示动脉瘤性蛛网膜下腔出血后挥发性镇静对患者结局无负面影响。

研究设计与样本

  • 回顾性收集2016至2022年间接受机械通气且镇静至少180小时的动脉瘤性蛛网膜下腔出血患者数据。
  • 按镇静方式分为静脉镇静对照组和挥发性镇静研究组,进行回顾性比较分析。
  • 采用逻辑回归分析识别迟发性脑缺血、脑血管痉挛、迟发性脑缺血相关梗死及功能预后的独立预测因素。
  • 共纳入99例患者,中位年龄58岁(四分位距:52-65岁)。

主要发现

  • 47例(47%)接受静脉镇静,52例(53%)接受(附加)挥发性镇静,其中异氟烷30例(58%)、七氟烷22例(42%),中位持续时间为169小时(范围:5-298小时)。
  • 两组在迟发性脑缺血、血管造影性脑血管痉挛、迟发性脑缺血相关梗死或功能预后方面均无显著差异。
  • 多因素逻辑回归分析中,挥发性麻醉药使用对迟发性脑缺血相关梗死发生率或患者功能预后无影响。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Volatile anesthetics have shown neuroprotective effects in preclinical studies, but clinical data on their use after aneurysmal subarachnoid hemorrhage (aSAH) are limited. This study aimed to analyze whether the use of volatile anesthetics for neurocritical care sedation affects the incidence of delayed cerebral ischemia (DCI), cerebral vasospasm (CVS), DCI-related infarction, or functional outcome. METHODS: Data were retrospectively collected for ventilated aSAH patients (2016-2022), who received sedation for at least 180 hours. For comparative analysis, patients were assigned to a control and a study group according to the sedation used (intravenous vs. volatile sedation). Logistic regression analysis was performed to identify independent predictors of DCI, CVS, DCI-related infarction, and functional outcome. RESULTS: Ninety-nine patients with a median age of 58 years (interquartile range: 52-65 years) were included. Forty-seven patients (47%) received intravenous sedation, while 52 patients (53%) received (additional) volatile sedation with isoflurane (n = 30, 58%) or sevoflurane (n = 22, 42%) for a median duration of 169 hours (range: 5-298 hours). There were no significant differences between the 2 groups regarding the occurrence of DCI, angiographic CVS, DCI-related infarction, or functional outcome. In a multivariable logistic regression analysis, the use of volatile anesthetics had no impact on the incidence of DCI-related infarction or the patients' functional outcome. CONCLUSIONS: Volatile sedation in aSAH patients is not associated with the incidence of DCI, CVS, DCI-related infarction, or functional outcome. Although we could not demonstrate neuroprotective effects of volatile anesthetics, our results suggest that volatile sedation after aSAH has no negative effect on the patient's outcome.

来源:World Neurosurg,查看原文。版权归原作者所有。

引用

  1. Küchler J, Schwachenwald B, Matone MV, et al. Volatile Sedation in Neurointensive Care Patients After Aneurysmal Subarachnoid Hemorrhage: Effects on Delayed Cerebral Ischemia, Cerebral Vasospasm, and Functional Outcome. World Neurosurg. 2024. PMID: 39182830. doi:10.1016/j.wneu.2024.08.097

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。